192 related articles for article (PubMed ID: 38066851)
21. Juvenile myelomonocytic leukemia in the molecular era: a clinician's guide to diagnosis, risk stratification, and treatment.
Wintering A; Dvorak CC; Stieglitz E; Loh ML
Blood Adv; 2021 Nov; 5(22):4783-4793. PubMed ID: 34525182
[TBL] [Abstract][Full Text] [Related]
22. JMML genomics and decisions.
Niemeyer CM
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):307-312. PubMed ID: 30504325
[TBL] [Abstract][Full Text] [Related]
23. Juvenile myelomonocytic leukemia: who's the driver at the wheel?
Niemeyer CM; Flotho C
Blood; 2019 Mar; 133(10):1060-1070. PubMed ID: 30670449
[TBL] [Abstract][Full Text] [Related]
24. Integrated molecular profiling of juvenile myelomonocytic leukemia.
Murakami N; Okuno Y; Yoshida K; Shiraishi Y; Nagae G; Suzuki K; Narita A; Sakaguchi H; Kawashima N; Wang X; Xu Y; Chiba K; Tanaka H; Hama A; Sanada M; Ito M; Hirayama M; Watanabe A; Ueno T; Kojima S; Aburatani H; Mano H; Miyano S; Ogawa S; Takahashi Y; Muramatsu H
Blood; 2018 Apr; 131(14):1576-1586. PubMed ID: 29437595
[TBL] [Abstract][Full Text] [Related]
25. Nf1 and Sh2b3 mutations cooperate in vivo in a mouse model of juvenile myelomonocytic leukemia.
Morales CE; Stieglitz E; Kogan SC; Loh ML; Braun BS
Blood Adv; 2021 Sep; 5(18):3587-3591. PubMed ID: 34464969
[TBL] [Abstract][Full Text] [Related]
26. Somatic mosaicism for oncogenic NRAS mutations in juvenile myelomonocytic leukemia.
Doisaki S; Muramatsu H; Shimada A; Takahashi Y; Mori-Ezaki M; Sato M; Kawaguchi H; Kinoshita A; Sotomatsu M; Hayashi Y; Furukawa-Hibi Y; Yamada K; Hoshino H; Kiyoi H; Yoshida N; Sakaguchi H; Narita A; Wang X; Ismael O; Xu Y; Nishio N; Tanaka M; Hama A; Koike K; Kojima S
Blood; 2012 Aug; 120(7):1485-8. PubMed ID: 22753870
[TBL] [Abstract][Full Text] [Related]
27. Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium.
Chan RJ; Cooper T; Kratz CP; Weiss B; Loh ML
Leuk Res; 2009 Mar; 33(3):355-62. PubMed ID: 18954903
[TBL] [Abstract][Full Text] [Related]
28. Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia.
Stieglitz E; Mazor T; Olshen AB; Geng H; Gelston LC; Akutagawa J; Lipka DB; Plass C; Flotho C; Chehab FF; Braun BS; Costello JF; Loh ML
Nat Commun; 2017 Dec; 8(1):2127. PubMed ID: 29259179
[TBL] [Abstract][Full Text] [Related]
29. [GATA1-mutation associated leukemia in children with trisomy 21 mosaic].
Reinhardt D; Reinhardt K; Neuhoff C; Sander A; Klusmann JH; Pekrun A; Sauerbrey A; von Stackelberg A; Rössig C; Creutzig U; Kolenova A
Klin Padiatr; 2012 Apr; 224(3):153-5. PubMed ID: 22513796
[TBL] [Abstract][Full Text] [Related]
30. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia.
Loh ML; Sakai DS; Flotho C; Kang M; Fliegauf M; Archambeault S; Mullighan CG; Chen L; Bergstraesser E; Bueso-Ramos CE; Emanuel PD; Hasle H; Issa JP; van den Heuvel-Eibrink MM; Locatelli F; Stary J; Trebo M; Wlodarski M; Zecca M; Shannon KM; Niemeyer CM
Blood; 2009 Aug; 114(9):1859-63. PubMed ID: 19571318
[TBL] [Abstract][Full Text] [Related]
31. Myelodysplastic and myeloproliferative disorders of childhood.
Hasle H
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):598-604. PubMed ID: 27913534
[TBL] [Abstract][Full Text] [Related]
32. Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network.
Caye A; Strullu M; Guidez F; Cassinat B; Gazal S; Fenneteau O; Lainey E; Nouri K; Nakhaei-Rad S; Dvorsky R; Lachenaud J; Pereira S; Vivent J; Verger E; Vidaud D; Galambrun C; Picard C; Petit A; Contet A; Poirée M; Sirvent N; Méchinaud F; Adjaoud D; Paillard C; Nelken B; Reguerre Y; Bertrand Y; Häussinger D; Dalle JH; Ahmadian MR; Baruchel A; Chomienne C; Cavé H
Nat Genet; 2015 Nov; 47(11):1334-40. PubMed ID: 26457648
[TBL] [Abstract][Full Text] [Related]
33. Proteomic Analysis of an Induced Pluripotent Stem Cell Model Reveals Strategies to Treat Juvenile Myelomonocytic Leukemia.
Pearson S; Guo B; Pierce A; Azadbakht N; Brazzatti JA; Patassini S; Mulero-Navarro S; Meyer S; Flotho C; Gelb BD; Whetton AD
J Proteome Res; 2020 Jan; 19(1):194-203. PubMed ID: 31657576
[TBL] [Abstract][Full Text] [Related]
34. [Molecular mechanism and treatment of juvenile myelomonocytic leukemia (JMML)].
Manabe A
Rinsho Ketsueki; 2012 Aug; 53(8):729-33. PubMed ID: 22975811
[No Abstract] [Full Text] [Related]
35. Juvenile myelomonocytic leukemia: epidemiology, etiopathogenesis, diagnosis, and management considerations.
Yoshimi A; Kojima S; Hirano N
Paediatr Drugs; 2010; 12(1):11-21. PubMed ID: 20034338
[TBL] [Abstract][Full Text] [Related]
36. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options.
Niemeyer CM; Kratz CP
Br J Haematol; 2008 Mar; 140(6):610-24. PubMed ID: 18302710
[TBL] [Abstract][Full Text] [Related]
37. Juvenile myelomonocytic leukaemia and Noonan syndrome.
Strullu M; Caye A; Lachenaud J; Cassinat B; Gazal S; Fenneteau O; Pouvreau N; Pereira S; Baumann C; Contet A; Sirvent N; Méchinaud F; Guellec I; Adjaoud D; Paillard C; Alberti C; Zenker M; Chomienne C; Bertrand Y; Baruchel A; Verloes A; Cavé H
J Med Genet; 2014 Oct; 51(10):689-97. PubMed ID: 25097206
[TBL] [Abstract][Full Text] [Related]
38. Somatic mutations activating Wiskott-Aldrich syndrome protein concomitant with RAS pathway mutations in juvenile myelomonocytic leukemia patients.
Coppe A; Nogara L; Pizzuto MS; Cani A; Cesaro S; Masetti R; Locatelli F; Te Kronnie G; Basso G; Bortoluzzi S; Bresolin S
Hum Mutat; 2018 Apr; 39(4):579-587. PubMed ID: 29316027
[TBL] [Abstract][Full Text] [Related]
39. Neonatal Leukemia.
Brown PA
Clin Perinatol; 2021 Mar; 48(1):15-33. PubMed ID: 33583502
[TBL] [Abstract][Full Text] [Related]
40. The Clinical Landscape of NRAS- mutated Juvenile Myelomonocytic Leukemia-like Myeloproliferation Includes Children With Costello Syndrome.
Pabari R; Chun K; Naqvi A
J Pediatr Hematol Oncol; 2023 Apr; 45(3):e401-e405. PubMed ID: 35665722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]